The global atipamezole market is estimated to grow at a robust CAGR during the forecast period.
Atipamezole is an alpha2 adrenergic receptor opponent drug that replaces the adverse effects of relaxing and pain killer drugs like medetomidine, xylazine, amitraz, and detomidine in animals. These drugs are mainly used as a medicine, particularly for animals like dogs and sometimes for cats. This drug is used in clinical trials in human beings for treating Parkinson’s disease.
MARKET DRIVERS
The strategies adopted by key players for their product approvals, the launch of new therapies are some factors that drive the atipamezole market. Mergers, acquisitions, and collaborations also influence the market. Growing demand for a wide range of usage of these drugs across the world, particularly for animals in dogs, is boosting the market. Initial acquisition of advanced therapeutics of the atipamezole and well-equipped healthcare infrastructure is also surging the market during the review period. Growing government initiatives in developing countries towards the modernization of animal healthcare structure and rise in awareness about advanced therapeutics are based on the factors for the growth of the atipamezole market during the market over the analysis period. Increasing animal health awareness and animal welfare accelerate the market.
MARKET RESTRAINS
Stringent guidelines to be followed for the approval and launch of the new product devices or therapies are hampering the atipamezole market growth. The cost of these drugs may be so expensive, which is not affordable, also restrict the market growth. Adverse effects after the treatment using these drugs are restraining the market growth over the period. Also, the strict rules related to the safety and efficiency of the atipamezole market growth over the foreseen period.
REPORT COVERAGE
|
REPORT METRIC |
DETAILS |
|
Market Size Available |
2019 to 2025 |
|
Base Year |
2019 |
|
Forecast Period |
2020 to 2025 |
|
Segments Analysed |
By Application, Route of Administration, and Region |
|
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
|
Regions Analysed |
North America, Europe, Asia Pacific, Latin America, Middle East, and Africa |
|
Companies Analysed |
Pfizer Inc., Orion Corporation, Alvetra & Werfft GmbH, CP Pharmaceuticals Ltd., Sogeval Laboratories, Inc., VetPharm, Inc., Ceva Sant Animale S.A., Dr. E. Graeub AG, Axience SAS, and Eli Lilly |
This research report on the global atipamezole market has been segmented, and sub-segmented has been application, route of administration, and region.
Atipamezole Market - By Application
Atipamezole Market - By Route of Administration
Atipamezole Market - By Region
North America has the leading market for Atipamezole in the world, which is followed by Europe and the Asia Pacific regions. Asia Pacific region is expected to have the fastest growth rate during the forecast period, owing to the growing population bases in the area.
TOP COMPANIES IN THE MARKET
Promising companies leading the global atipamezole market profiled in the report are Pfizer Inc., Orion Corporation, Alvetra & Werfft GmbH, CP Pharmaceuticals Ltd., Sogeval Laboratories, Inc., VetPharm, Inc., Ceva Sant Animale S.A., Dr. E. Graeub AG, Axience SAS and Eli Lilly.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemiology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Application
5.1.1 Anti-Sedatives
5.1.2 Others
5.1.3 Y-o-Y Growth Analysis, By Application
5.1.4 Market Attractiveness Analysis, By Application
5.1.5 Market Share Analysis, By Application
5.2 Route of Administration
5.2.1 Intramuscular
5.2.2 Intravenous
5.2.3 Subcutaneous
5.2.4 Intraperitoneal
5.2.5 Y-o-Y Growth Analysis, By Route of Administration
5.2.6 Market Attractiveness Analysis, By Route of Administration
5.2.7 Market Share Analysis, By Route of Administration
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Application
6.1.3.2 By Route of Administration
6.1.4 Market Attractiveness Analysis
6.1.3.1 By Application
6.1.3.2 By Route of Administration
6.1.5 Market Share Analysis
6.1.3.1 By Application
6.1.3.2 By Route of Administration
6.2 North America
6.2.1 Introduction
6.2.2 United States
6.2.3 Canada
6.3 Europe
6.3.1 Introduction
6.3.2 U.K
6.3.3 Spain
6.3.4 Germany
6.3.5 Italy
6.3.6 France
6.4 Asia-Pacific
6.4.1 Introduction
6.4.2 China
6.4.3 India
6.4.4 Japan
6.4.5 Australia
6.4.6 South Korea
6.5 Latin America
6.5.1 Introduction
6.5.2 Brazil
6.5.3 Argentina
6.5.4 Mexico
6.5.5 Rest of Latin America
6.6 Middle East & Africa
6.6.1 Introduction
6.6.2 Middle-East
6.6.3 Africa
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Pfizer Inc.
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Orion Corporation
8.3 Alvetra & Werfft GmbH
8.4 CP Pharmaceuticals Ltd.
8.5 Sogeval Laboratories, Inc.
8.6 VetPharm, Inc.
8.7 Ceva Sant Animale S.A.
8.8 Dr. E. Graeub AG
8.9 A x ience SAS
8.10 Eli Lilly and Company
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, Collaborations, and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Feb 2020
Feb 2020
Feb 2020
